article thumbnail

Why cancer medicines are and continue to be vulnerable to drug shortages

Quality Matters

Analysis leveraging USP’s Medicine Supply Map suggests many of the essential cancer medicines have inherently vulnerable supply chains and are at greater risk for shortage compared to other generic medicines. The closer the risk score is to 100%, the greater the risk for that drug to be in shortage in the next 12 months.

article thumbnail

Navigating tariffs and diplomacy: the future of India-US pharmaceutical trade

Pharmaceutical Technology

Amid President Donald Trump’s stated desire to sharply reduce drug prices on the US market, India has also proposed to supply generic medicines at between 20% and 25% of the current reference branded prices, for three years after originator patent expiry. For a demo or further information, please contact us here.